BC Innovations | Jul 21, 2016
Distillery Therapeutics
Therapeutics: Glutamic-pyruvic transaminase 2 (GPT2); activating transcription factor 4 (ATF4); phosphoinositide 3-kinase catalytic subunit α polypeptide (PI3KC
Cancer INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting GPT2 or ATF4 could help treat PI3KCA-mutant colorectal cancer. In tumor samples from colorectal cancer patients, GPT2 expression was higher in tumors...
